482 related articles for article (PubMed ID: 32482852)
1. MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis.
Kim J; Kwon H; Shin YK; Song G; Lee T; Kim Y; Jeong W; Lee U; Zhang X; Nam G; Jeung HC; Kim W; Jho EH
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13529-13540. PubMed ID: 32482852
[TBL] [Abstract][Full Text] [Related]
2. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
4. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.
Chang L; Azzolin L; Di Biagio D; Zanconato F; Battilana G; Lucon Xiccato R; Aragona M; Giulitti S; Panciera T; Gandin A; Sigismondo G; Krijgsveld J; Fassan M; Brusatin G; Cordenonsi M; Piccolo S
Nature; 2018 Nov; 563(7730):265-269. PubMed ID: 30401838
[TBL] [Abstract][Full Text] [Related]
5. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
6. The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7.
Chaulk SG; Lattanzi VJ; Hiemer SE; Fahlman RP; Varelas X
J Biol Chem; 2014 Jan; 289(4):1886-91. PubMed ID: 24324261
[TBL] [Abstract][Full Text] [Related]
7. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
8. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
9. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
10. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
Nishina H
Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
[TBL] [Abstract][Full Text] [Related]
11. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
[TBL] [Abstract][Full Text] [Related]
12. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
13. Metabolic control of YAP and TAZ by the mevalonate pathway.
Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
[TBL] [Abstract][Full Text] [Related]
14. HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.
Yuan B; Liu J; Shi A; Cao J; Yu Y; Zhu Y; Zhang C; Qiu Y; Luo H; Shi J; Cao X; Xu P; Shen L; Liang T; Zhao B; Feng XH
EMBO J; 2023 Feb; 42(4):e111549. PubMed ID: 36598329
[TBL] [Abstract][Full Text] [Related]
15. The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis.
Kovar H; Bierbaumer L; Radic-Sarikas B
Cells; 2020 Apr; 9(4):. PubMed ID: 32326412
[TBL] [Abstract][Full Text] [Related]
16. New insights into YAP/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities?
Shreberk-Shaked M; Oren M
Mol Oncol; 2019 Jun; 13(6):1335-1341. PubMed ID: 31050214
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
Kim M; Kim T; Johnson RL; Lim DS
Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
[TBL] [Abstract][Full Text] [Related]
18. An overview of signaling pathways regulating YAP/TAZ activity.
Heng BC; Zhang X; Aubel D; Bai Y; Li X; Wei Y; Fussenegger M; Deng X
Cell Mol Life Sci; 2021 Jan; 78(2):497-512. PubMed ID: 32748155
[TBL] [Abstract][Full Text] [Related]
19. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
Pobbati AV; Hong W
Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
[TBL] [Abstract][Full Text] [Related]
20. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
